Skip to content
Screener

Vaxcyte, Inc. PCVX Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Moderna logo
ModernaMRNA
$1.72B+34.5%
Novavax logo
NovavaxNVAX
$191.46M-24.5%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$501.31M+62.4%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Effect of exchange rate changes on cash and cash equivalents(664)1,172
Net increase (decrease) in cash, cash equivalents and restricted cash86,884(41,026)
Cash, cash equivalents and restricted cash, beginning of period175,425389,195
Cash, cash equivalents and restricted cash, end of period$262,309$348,169
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$260,843$346,850
Restricted cash1,4661,319
Cash, cash equivalents and restricted cash$262,309$348,169

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s cash & equivalents?
Vaxcyte, Inc. (PCVX) reported cash & equivalents of $262.31M in Q1 2026.
How has Vaxcyte, Inc.'s cash & equivalents changed year-over-year?
Vaxcyte, Inc.'s cash & equivalents decreased by 24.7% year-over-year, from $348.17M to $262.31M.
What is the long-term trend for Vaxcyte, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s cash & equivalents has grown at a -14.6% compound annual growth rate (CAGR), from $386.2M to $175.43M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Vaxcyte, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude